Imexpharm Corp
VN:IMP

Watchlist Manager

Imexpharm Corp

VN:IMP

Watchlist

Dividends

Price: 48 050 VND -0.93%

Market Cap: 7.4T VND

Have any thoughts about
Imexpharm Corp?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Berkshire Hathaway Inc NYSE:BRK.A	Financial Services
US	Bank of America Corp NYSE:BAC	Banking
US	Mastercard Inc NYSE:MA	Technology
US	UnitedHealth Group Inc NYSE:UNH	Health Care
US	Exxon Mobil Corp NYSE:XOM	Energy
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	Palantir Technologies Inc NYSE:PLTR	Technology
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	3M Co NYSE:MMM	Industrial Conglomerates
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Walmart Inc NYSE:WMT	Retail
US	Verizon Communications Inc NYSE:VZ	Telecommunication

Add Price Alert

Price Target:

Last Price: 48050 VND

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

IMP Alert

Imexpharm Corp

48050

-450 (-0.93%)

52 Week Range	25 066.1469 97 000
Price Target

We'll email you a reminder when the closing price reaches VND.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Johnson & Johnson NYSE:JNJ	US
	Berkshire Hathaway Inc NYSE:BRK.A	US
	Bank of America Corp NYSE:BAC	US
	Mastercard Inc NYSE:MA	US
	UnitedHealth Group Inc NYSE:UNH	US
	Exxon Mobil Corp NYSE:XOM	US
	Pfizer Inc NYSE:PFE	US
	Palantir Technologies Inc NYSE:PLTR	US
	Nike Inc NYSE:NKE	US
	Visa Inc NYSE:V	US
	Alibaba Group Holding Ltd NYSE:BABA	CN
	3M Co NYSE:MMM	US
	JPMorgan Chase & Co NYSE:JPM	US
	Coca-Cola Co NYSE:KO	US
	Walmart Inc NYSE:WMT	US
	Verizon Communications Inc NYSE:VZ	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Imexpharm Corp

What unique competitive advantages
does Imexpharm Corp hold over its rivals?

What risks and challenges
does Imexpharm Corp face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Imexpharm Corp.

What unique competitive advantages
does Imexpharm Corp hold over its rivals?

What risks and challenges
does Imexpharm Corp face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Imexpharm Corp.

Provide P/S
for Imexpharm Corp.

Provide P/E
for Imexpharm Corp.

Provide P/OCF
for Imexpharm Corp.

Provide P/FCFE
for Imexpharm Corp.

Provide P/B
for Imexpharm Corp.

Provide EV/S
for Imexpharm Corp.

Provide EV/GP
for Imexpharm Corp.

Provide EV/EBITDA
for Imexpharm Corp.

Provide EV/EBIT
for Imexpharm Corp.

Provide EV/OCF
for Imexpharm Corp.

Provide EV/FCFF
for Imexpharm Corp.

Provide EV/IC
for Imexpharm Corp.

Show me price targets
for Imexpharm Corp made by professional analysts.

What are the Revenue projections
for Imexpharm Corp?

How accurate were the past Revenue estimates
for Imexpharm Corp?

What are the Net Income projections
for Imexpharm Corp?

How accurate were the past Net Income estimates
for Imexpharm Corp?

What are the EPS projections
for Imexpharm Corp?

How accurate were the past EPS estimates
for Imexpharm Corp?

What are the EBIT projections
for Imexpharm Corp?

How accurate were the past EBIT estimates
for Imexpharm Corp?

Compare the revenue forecasts
for Imexpharm Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Imexpharm Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Imexpharm Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of Imexpharm Corp compared to its peers.

Compare the P/E ratios
of Imexpharm Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing Imexpharm Corp with its peers.

Analyze the financial leverage
of Imexpharm Corp compared to its main competitors.

Show all profitability ratios
for Imexpharm Corp.

Provide ROE
for Imexpharm Corp.

Provide ROA
for Imexpharm Corp.

Provide ROIC
for Imexpharm Corp.

Provide ROCE
for Imexpharm Corp.

Provide Gross Margin
for Imexpharm Corp.

Provide Operating Margin
for Imexpharm Corp.

Provide Net Margin
for Imexpharm Corp.

Provide FCF Margin
for Imexpharm Corp.

Show all solvency ratios
for Imexpharm Corp.

Provide D/E Ratio
for Imexpharm Corp.

Provide D/A Ratio
for Imexpharm Corp.

Provide Interest Coverage Ratio
for Imexpharm Corp.

Provide Altman Z-Score Ratio
for Imexpharm Corp.

Provide Quick Ratio
for Imexpharm Corp.

Provide Current Ratio
for Imexpharm Corp.

Provide Cash Ratio
for Imexpharm Corp.

What is the historical Revenue growth
over the last 5 years for Imexpharm Corp?

What is the historical Net Income growth
over the last 5 years for Imexpharm Corp?

What is the current Free Cash Flow
of Imexpharm Corp?

Discuss the annual earnings per share (EPS)
trend over the past five years for Imexpharm Corp.

EV/EBITDA
Enterprise Value to EBITDA

16.4

Current

5.5

Median

13.5

Industry

Higher than median

Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA

16.4

Enterprise Value

7.2T VND

EBITDA

441.1B VND

All Countries

Forward Multiples

			Market Cap	EV/EBITDA
VN	I	Imexpharm Corp VN:IMP	7.4T VND	16.4
JP	N	Nichi-Iko Pharmaceutical Co Ltd TSE:4541	776 550.9T JPY	-5 459 134.4
US		Eli Lilly and Co NYSE:LLY	755.8B USD	48.5
UK		Dechra Pharmaceuticals PLC LSE:DPH	440.4B GBP	3 846.3
DK		Novo Nordisk A/S CSE:NOVO B	2.7T DKK	20.2
US		Johnson & Johnson NYSE:JNJ	351.1B USD	11.6
US		Merck & Co Inc NYSE:MRK	251.8B USD	10.5
CH		Roche Holding AG SIX:ROG	200.1B CHF	9.8
UK		AstraZeneca PLC LSE:AZN	161.8B GBP	169.4
CH		Novartis AG SIX:NOVN	171.5B CHF	9.4
US		Pfizer Inc NYSE:PFE	151.5B USD	10.6

				EBITDA Growth	EV/EBITDA to Growth
VN	I	Imexpharm Corp VN:IMP	Average EV/EBITDA: 415.3 16.4	N/A	N/A
JP	N	Nichi-Iko Pharmaceutical Co Ltd TSE:4541	Negative Multiple: -5 459 134.4	N/A	N/A
US		Eli Lilly and Co NYSE:LLY	48.5	195%	0.2
UK		Dechra Pharmaceuticals PLC LSE:DPH	3 846.3	151%	25.5
DK		Novo Nordisk A/S CSE:NOVO B	20.2	84%	0.2
US		Johnson & Johnson NYSE:JNJ	11.6	14%	0.8
US		Merck & Co Inc NYSE:MRK	10.5	331%	0
CH		Roche Holding AG SIX:ROG	9.8	23%	0.4
UK		AstraZeneca PLC LSE:AZN	169.4	64%	2.7
CH		Novartis AG SIX:NOVN	9.4	8%	1.2
US		Pfizer Inc NYSE:PFE	10.6	31%	0.3

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward

EV/EBITDA

13.9

2-Years Forward

EV/EBITDA

12.3

3-Years Forward

EV/EBITDA

N/A

	Franklin Covey Co NYSE:FC	36.87 USD 1.57%
	Mohawk Industries Inc NYSE:MHK	120.19 USD 0.54%
	Ardmore Shipping Corp NYSE:ASC	12.12 USD 2.02%
	ASGN Inc NYSE:ASGN	84.15 USD 0.71%
	Skyworks Solutions Inc NASDAQ:SWKS	90.35 USD 0.18%
	Weatherford International PLC NASDAQ:WFRD	68.07 USD 1.95%

	Johnson & Johnson NYSE:JNJ	145.85 USD 0.4%
	Bank of America Corp NYSE:BAC	44.38 USD 1.12%
	Mastercard Inc NYSE:MA	535.71 USD 1.28%
	Salesforce Inc NYSE:CRM	344.43 USD 0.45%
	Abbvie Inc NYSE:ABBV	180 USD 0.9%
	Home Depot Inc NYSE:HD	396.14 USD 0.94%

	Arista Networks Inc NYSE:ANET	114.65 USD 1.38%
	Visa Inc NYSE:V	320.65 USD 1.08%
	Texas Pacific Land Corp NYSE:TPL	1 161.2 USD 1.91%
	KLA Corp NASDAQ:KLAC	650.53 USD 0.39%
	Manhattan Associates Inc NASDAQ:MANH	282.27 USD 1.24%
	Pinduoduo Inc NASDAQ:PDD	99.72 USD -0.86%

	Salesforce Inc NYSE:CRM	344.43 USD 0.45%
	Accenture PLC NYSE:ACN	361.63 USD 0.8%
	ServiceNow Inc NYSE:NOW	1 105.56 USD 1.59%
	EOG Resources Inc NYSE:EOG	120.83 USD 0.82%
	Copart Inc NASDAQ:CPRT	59.11 USD 1.29%
	Applied Materials Inc NASDAQ:AMAT	168.37 USD 0.54%

Imexpharm Corp
VN:IMP

EV/EBITDA
Enterprise Value to EBITDA

EV/EBITDA Forward Multiples

See Also

Company

Help

Tools

Stocks

Imexpharm Corp VN:IMP

EV/EBITDA Enterprise Value to EBITDA

EV/EBITDA Forward Multiples

See Also

Company

Help

Tools

Stocks

Imexpharm Corp
VN:IMP

EV/EBITDA
Enterprise Value to EBITDA